Belite Bio's Stargardt Drug Wins FDA Priority Review; PDUFA Set for Feb. 2027

What happened

Belite Bio, a biopharmaceutical company developing treatments for inherited retinal diseases, announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tinlarebant for Stargardt disease type 1 (STGD1). The FDA granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027.

The company also presented additional positive secondary endpoint data, specifically quantitative autofluorescence (qAF) results, from its Phase 3 DRAGON trial. According to eye care trade publication Eyewire, the FDA's acceptance and Priority Review designation "underscores the immediate need among the Stargardt disease community for an approved treatment."

Belite Bio separately released unaudited second quarter 2026 financial results, reporting increased operating expenses and a cash position near $780 million, as reported by Yahoo Finance.

Source verification

This article is based on the company's own news release (via its investor relations site), coverage by Eyewire, Ophthalmology Times, The Globe and Mail, and Yahoo Finance. The FDA acceptance was originally flagged in posts on the social media platform X, but the same information is confirmed by the company's official announcement and multiple trade publications.

The company's press release, quoted in Eyewire, includes a quote from Belite Bio's CEO praising the FDA's decision. The PDUFA date of February 12, 2027, is consistent across all corroborating sources.

What this means

A New Drug Application (NDA) is the formal request the FDA reviews to decide whether a new medicine can be sold in the U.S. Acceptance of an NDA means the FDA has determined the application is complete enough to review, not that the drug is approved.

Priority Review shortens the FDA's review target from the standard 10 months to 6 months from the date of acceptance. Here, that sets a target decision date of February 12, 2027—meaning the FDA will likely announce its approval decision on or before that date, though the timeline can shift.

Stargardt disease type 1 is a rare inherited eye disease that causes progressive vision loss, and there are currently no FDA-approved treatments for it. Tinlarebant, an oral drug taken once daily, is being developed as a potential first-in-class therapy, as noted by Ophthalmology Times.

The qAF secondary endpoint data relates to a measure of lipofuscin, a pigment that builds up in the retina in Stargardt disease. Positive qAF results suggest tinlarebant may slow the disease process, but these are secondary endpoint results, not the primary efficacy measure.

The company's large cash position—around $780 million per the Q2 release—suggests it has resources to support commercial preparation, which the company noted was underway in its Q2 update. Stock rose 2.63% to $155.71 on the announcement day, reflecting investor optimism about the regulatory progress.